financetom
Business
financetom
/
Business
/
Riley Permian Q3 sales up, raises 2025 oil production forecast
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Riley Permian Q3 sales up, raises 2025 oil production forecast
Nov 5, 2025 3:14 PM

Overview

* Riley Permian Q3 revenue totals $107 mln, net income at $16 mln, EPS $0.77

* Company increased annual dividend by 5% to $0.40 per share

* Oil production increased 21% quarter-over-quarter, driven by Silverback asset integration

Outlook

* Company raises full-year oil production guidance by 2% at midpoint

* Company maintains full-year total capital expenditures guidance

* Company expects midstream infrastructure in New Mexico operational by 2026

Result Drivers

* SILVERBACK ACQUISITION - Integration of Silverback assets increased oil production and reduced costs

* FREE CASH FLOW GENERATION - Execution of development and capital plan generated significant free cash flow

* MIDSTREAM AND POWER PROJECTS - Progress on midstream and power generation projects to scale operations

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Oil & $106.85

Gas mln

Sales

Q3 EPS $0.77

Q3 $64.04

Adjusted mln

EBITDAX

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the oil & gas exploration and production peer group is "buy"

* Wall Street's median 12-month price target for Riley Exploration Permian Inc ( REPX ) is $60.00, about 57.9% above its November 4 closing price of $25.25

* The stock recently traded at 5 times the next 12-month earnings vs. a P/E of 5 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
ADB to provide $410 million package for Barrick-run Pakistan mine, sources say
ADB to provide $410 million package for Barrick-run Pakistan mine, sources say
Aug 21, 2025
* ADB to provide $410 million package for copper-gold mine * Package includes a $300 million in loans to Barrick Gold ( B ) (Updates throughout) By Saeed Shah and Ariba Shahid ISLAMABAD, Aug 21 (Reuters) - The Asian Development Bank will provide a $410 million financing package to help develop Pakistan's Reko Diq copper mine, one of the world's...
AbbVie Says 2nd Phase 3 Trial Evaluating Upadacitinib for Alopecia Areata Met Primary Endpoint
AbbVie Says 2nd Phase 3 Trial Evaluating Upadacitinib for Alopecia Areata Met Primary Endpoint
Aug 21, 2025
09:29 AM EDT, 08/21/2025 (MT Newswires) -- AbbVie ( ABBV ) said Thursday that topline results from the second of two pivotal studies of a phase 3 trial showed that upadacitinib improved scalp and non-scalp hair regrowth in adult and adolescent patients with severe alopecia areata. The study achieved the primary endpoint with 45.2% and 55% of patients treated with...
Caterpillar, Hunt Energy Collaborate to Provide Power Services for Data Centers
Caterpillar, Hunt Energy Collaborate to Provide Power Services for Data Centers
Aug 21, 2025
09:27 AM EDT, 08/21/2025 (MT Newswires) -- Caterpillar ( CAT ) and Hunt Energy said Thursday that they have formed a collaboration to provide power services for data centers. Financial details of the collaboration were not disclosed. Caterpillar ( CAT ) will use its portfolio of power services and will provide monitoring and servicing products, the companies said. Hunt will...
Crinetics Pharmaceuticals Gets FDA Orphan Drug Designation for Atumelnant
Crinetics Pharmaceuticals Gets FDA Orphan Drug Designation for Atumelnant
Aug 21, 2025
09:25 AM EDT, 08/21/2025 (MT Newswires) -- Crinetics Pharmaceuticals ( CRNX ) said Thursday the US Food and Drug Administration has granted orphan drug designation to atumelnant, its oral drug candidate for classic congenital adrenal hyperplasia. The company said the designation follows phase 2 trial results that indicated reductions in key biomarkers and clinical symptoms in adults with the condition....
Copyright 2023-2026 - www.financetom.com All Rights Reserved